» Articles » PMID: 36176908

Combination Therapy Using Microwave Ablation and D-mannose-chelated Iron Oxide Nanoparticles Inhibits Hepatocellular Carcinoma Progression

Overview
Publisher Elsevier
Specialty Pharmacology
Date 2022 Sep 30
PMID 36176908
Authors
Affiliations
Soon will be listed here.
Abstract

Despite being a common therapy for hepatocellular carcinoma (HCC), insufficient thermal ablation can leave behind tumor residues that can cause recurrence. This is believed to augment M2 inflammatory macrophages that usually play a pro-tumorigenic role. To address this problem, we designed d-mannose-chelated iron oxide nanoparticles (man-IONPs) to polarize M2-like macrophages into the antitumor M1 phenotype. and experiments demonstrated that man-IONPs specifically targeted M2-like macrophages and accumulated in peri-ablation zones after macrophage infiltration was augmented under insufficient microwave ablation (MWA). The nanoparticles simultaneously induced polarization of pro-tumorigenic M2 macrophages into antitumor M1 phenotypes, enabling the transformation of the immunosuppressive microenvironment into an immunoactivating one. Post-MWA macrophage polarization exerted robust inhibitory effects on HCC progression in a well-established orthotopic liver cancer mouse model. Thus, combining thermal ablation with man-IONPs can salvage residual tumors after insufficient MWA. These results have strong potential for clinical translation.

Citing Articles

Recent advances in the bench-to-bedside translation of cancer nanomedicines.

Liu Y, Zhang Y, Li H, Hu T Acta Pharm Sin B. 2025; 15(1):97-122.

PMID: 40041906 PMC: 11873642. DOI: 10.1016/j.apsb.2024.12.007.


Multifunctional biosynthesized magnetosome for multimodal imaging and combined therapy of tumor.

Han X, Wang X, Yan J, Song P, Wang Y, Kang Y Mater Today Bio. 2025; 30():101429.

PMID: 39839492 PMC: 11750283. DOI: 10.1016/j.mtbio.2024.101429.


Metal-based smart nanosystems in cancer immunotherapy.

Luo Y, He X, Du Q, Xu L, Xu J, Wang J Exploration (Beijing). 2024; 4(6):20230134.

PMID: 39713201 PMC: 11655314. DOI: 10.1002/EXP.20230134.


Solubilization techniques used for poorly water-soluble drugs.

Xie B, Liu Y, Li X, Yang P, He W Acta Pharm Sin B. 2024; 14(11):4683-4716.

PMID: 39664427 PMC: 11628819. DOI: 10.1016/j.apsb.2024.08.027.


Mechanistic studies of tumor-associated macrophage immunotherapy.

Cao J, Liu C Front Immunol. 2024; 15:1476565.

PMID: 39403370 PMC: 11472702. DOI: 10.3389/fimmu.2024.1476565.


References
1.
Taylor P, Gordon S, Martinez-Pomares L . The mannose receptor: linking homeostasis and immunity through sugar recognition. Trends Immunol. 2005; 26(2):104-10. DOI: 10.1016/j.it.2004.12.001. View

2.
Gao S, Lin H, Zhang H, Yao H, Chen Y, Shi J . Nanocatalytic Tumor Therapy by Biomimetic Dual Inorganic Nanozyme-Catalyzed Cascade Reaction. Adv Sci (Weinh). 2019; 6(3):1801733. PMC: 6364502. DOI: 10.1002/advs.201801733. View

3.
Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P . Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017; 14(7):399-416. PMC: 5480600. DOI: 10.1038/nrclinonc.2016.217. View

4.
Zhao J, Zhang Z, Xue Y, Wang G, Cheng Y, Pan Y . Anti-tumor macrophages activated by ferumoxytol combined or surface-functionalized with the TLR3 agonist poly (I : C) promote melanoma regression. Theranostics. 2019; 8(22):6307-6321. PMC: 6299704. DOI: 10.7150/thno.29746. View

5.
Shi L, Wang J, Ding N, Zhang Y, Zhu Y, Dong S . Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy. Nat Commun. 2019; 10(1):5421. PMC: 6883042. DOI: 10.1038/s41467-019-13204-3. View